PHAT News and Press, Phathom Pharmaceuticals Inc. From 04/21/20

One biotech IPO is scheduled for the week ahead, and pipeline activity indicates that a few more may be on the way. ORIC Pharmaceuticals (ORIC), a Phase 1 biotech developing small molecule therapies for treatment-resistant cancers, plans to raise $75 million at a $424 million market cap. The...

There were no IPOs this past week, but initial filings from a biotech and a Chinese issuer are keeping the IPO market moving. After another strong week, the IPO Index is now up about 35% from its March lows. As we pointed out in our 1Q20 IPO Review, the first IPOs to emerge from the shutdown...

FLORHAM PARK, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that company management will pa...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Phathom Pharmaceuticals (NASDAQ: PHAT ): FY GAAP EPS of -$22.45. Cash and cash equivalents of $243.8M Press Release More news on: Phathom Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,

Successfully Finished 2019 with Initiation of Two Pivotal Phase 3 Trials for Vonoprazan in Erosive Esophagitis (PHALCON-EE) and H. pylori Infection (PHALCON-HP) and Completion of $209M Initial Public Offering Temporarily Pausing New Patient Randomization in PHALCON-EE and PHAL...

FLORHAM PARK, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, Preside...

Today, we will study why Phathom Pharmaceuticals ( PHAT ) is an attractive pick in 2020. Company overview Launched by Takeda Pharmaceuticals ([[TKPHF]]) in May 2019, Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

MENLO PARK, Calif. , Jan. 16, 2020 /PRNewswire/ -- Frazier Healthcare Partners announced today the closing of Frazier Life Sciences X, L.P., exceeding its target and closing on more than $617 million in capital commitments in an oversubscribed fundraise. Investing in life sciences ...